Cisplatin resistance of the HNSCC cell line UT-SCC-26A can be overcome by stimulation of the EGF-receptor

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1181-1188

  Mandic, Robert ^a   Rodgarkia Dara, Chantal J ^b   Krohn, Vanessa ^a   Wiegand, Susanne ^a   Grénman, Reidar ^c   Werner, Jochen A ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Cisplatin; EGFR; HNSCC; Proliferation; Sensitivity

Indexed keywords

CISPLATIN; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; CANCER SURVIVAL; CELL CYCLE; CELL LINE; CELL PROLIFERATION; CELL VIABILITY; DISEASE COURSE; DRUG MECHANISM; DRUG RESISTANCE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL PROLIFERATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; HEAD AND NECK NEOPLASMS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 64949118624     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Dobrossy L: Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 24: 9-17, 2005.
2. Weichselbaum RR, Dunphy EJ, Beckett MA, Tybor AG, Moran WJ, Goldman ME, Vokes EE and Panje WR: Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck 11: 437-442, 1989.
3. Mandic R, Eikelkamp N, Peldszus R, Sadowski M, Sesterhenn AM, Dunne AA and Werner JA: Variations of EGF-R surface expression in squamous cell carcinomas of the head and neck region. Anticancer Res 21: 3413-3418, 2001.
4. Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, Butterfoss D, Xiang D, Zanation A, Yin X, Shockley WW, Weissler MC, Dressier LG, Shores CG, Yarbrough WG and Perou CM: Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5: 489-500, 2004.
5. Harari PM: Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer 11: 689-708, 2004.
6. Kies MS and Harari PM: Cetuximab (Imclone/Merck/Bristol- Myers Squibb). Curr Opin Investig Drugs 3: 1092-1100, 2002.
7. Herbst RS, Kim ES and Harari PM: IMC-C225, an anti- epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 1: 719-732,2001.
8. Mandic R, Rodgarkia-Dara CJ, Zhu L, Folz BJ, Bette M, Weihe E, Neubauer A and Werner JA: Treatment of HNSCC cell lines with the EGFR-specific inhibitor cetuximab (Erbitux) results in paradox phosphorylation of tyrosine 1173 in the receptor. FEBS Lett 580: 4793-4800, 2006.
9. Mandic R, Schamberger CJ, Muller JF, Geyer M, Zhu L, Carey TE, Grenman R, Dunne AA and Werner JA: Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53. Clin Cancer Res 11: 6845-6852, 2005.
10. Raben D,Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Baron AE, Zeng C, Johnson TK and Bunn PA Jr: The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer. Clin Cancer Res 11: 795-805,2005.
11. Kim S, Grandis JR, Rinaldo A, Takes RP and Ferlito A: Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer. Head Neck 30: 667-674, 2008.
12. Lansford C, Grenman R, Bier H, Somers KD, Kim S-Y, Whiteside TL, Clayman G and Carey TE: Head and neck cancers. In: Human Cell Culture Vol 2, Cancer Cell Lines Part 2. Masters J (ed.). Dordrecht (Holland), Kluwer Academic Press, pp. 185-255, 1999.
13. Genden EM, Ferlito A, Silver CE, Jacobson AS, Werner JA, Suarez C, Leemans CR, Bradley PJ and Rinaldo A: Evolution of the management of laryngeal cancer. Oral Oncol 43: 431-439, 2007.
14. Hasegawa Y, Goto M, Hanai N, Ijichi K, Terada A, Hyodo I, Ogawa T and Fukushima M: Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma. Oncology 73: 104-111, 2007.
15. Wong SF: Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27: 684-694, 2005.
16. Saba NF, Khuri FR and Shin DM: Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer. Oncology (Williston Park) 20: 153-161, 2006.
17. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007.
18. Loeffler-Ragg J, Witsch-Baumgartner M, Tzankov A, Hilbe W, Schwentner I, Sprinzl GM, Utermann G and Zwierzina H: Low incidence of mutations in EGFR kinase domain in Caucasian patients with head and neck squamous cell carcinoma. Eur J Cancer 42: 109-111,2006.
19. Evans DL, Tilby M and Dive C: Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res 54: 1596- 1603,1994.
20. Donaldson KL, Goolsby GL and Wahl AF: Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57: 847-855, 1994.
21. Frankenberg-Schwager M, Kirchermeier D, Greif G, Baer K, Becker M and Frankenberg D: Cisplatin-mediated DNA double- strand breaks in replicating but not in quiescent cells of the yeast Saccharomyces cerevisiae. Toxicology 212: 175-184, 2005.
22. Jares P, Fernandez PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J and Cardesa A: PRAD-l/cyclin Dl gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 54: 4813-4817, 1994.
23. Johnson DG and Walker CL: Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol 39: 295-312, 1999.
24. Allen JB, Zhou Z, Siede W, Friedberg EC and Elledge SJ: The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. Genes Dev 8: 2401-2415, 1994.
25. Murakami H and Okayama H: A kinase from fission yeast responsible for blocking mitosis in S phase. Nature 374: 817- 819,1995.
26. Matsuoka S, Huang M and Elledge SJ: Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science 282: 1893- 1897, 1998.
27. Pommier Y, Sordet O, Rao VA, Zhang H and Kohn KW: Targeting chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des 11: 2855-2872, 2005.
28. Antoni L, Sodha N, Collins I and Garrett MD: CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin? Nat Rev Cancer 7: 925-936, 2007.
29. Hirao A, Cheung A, Duncan G, Girard PM, Elia AJ, Wakeham A, Okada H, Sarkissian T, Wong JA, Sakai T, De SE, Bristow RG, Suda T, Lowe SW, Jeggo PA, Elledge SJ and Mak TW: Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM- independent manner. Mol Cell Biol 22: 6521-6532, 2002.